A.O. LOBKAREV, R.KH. KHAFIZYANOVA, O.A. LOBKAREV

Clinic of Ambulatory Urology, 12 Kamaleeva Ave., Kazan, Russian Federation, 420081

  Lobkarev A.O. — Ph. D (medicine), tel. +7 (843) 258-98-73, e-mail: [email protected], ORCID ID: 0000-0002-6618-4792

Khafizyanova R.Kh. — D. Sc. (medicine), Professor, tel. +7 (843) 292-59-02, e-mail: [email protected], ORCID ID: 0000-0002-3906-3661

Lobkarev O.A. — D. Sc. (medicine), Professor, tel. +7 (843) 222-52-31, e-mail: [email protected], ORCID ID: 0000-0001-5223-4261

 To study the changes of the Clinical Index of Chronic Prostatitis (CI-CP) and the International Index of Erectile Function (IIEF-5) during Tadalafil intake 5 mg once daily as monotherapy in men with erectile dysfunction (ED) in combination with chronic non-inflammatory prostatitis (CNIP).

Material and methods. The data from outpatient records of 88 patients diagnosed with «Chronic non-inflammatory prostatitis. Erectile dysfunction», treated in the Clinic of Ambulatory Urology (Kazan) in the period from 2012 to 2017, were studied. The following indicators were analyzed: CI-CP before the start of pharmacotherapy, as well as 28 days after the start of pharmacotherapy; IIEF-5) before the start of pharmacotherapy, as well as 28 days after the start of pharmacotherapy. Based on these indicators, discrete variation series were built, respectively, for CI-CP, containing integer values ​​from 0 points (no complaints) to 50 points (maximum points = most pronounced symptoms), and for IIEF, containing values ​​from 0 points (maximum degree of ED) to 25 points (normal = no ED).

The conclusions. Tadalafil at a dose of 5 mg per day leads to a statistically significant improvement in the International Index of Erectile Function (p<0.05). But the clinical efficacy of Tadalafil, calculated on the «Clinical Index of Chronic Prostatitis», is multivalued.

Key words: Tadalafil, chronic prostatitis, erectile dysfunction, pharmacotherapy.

 (For citation: Lobkarev A.O., Khafizyanova R.Kh., Lobkarev O.A. Unstudied tendencies of clinical effectiveness of Tadalafil in men with erectile dysfunction and chronic non-inflammatory prostatitis. Practical Medicine. 2018)

REFERENCES

1. Medik V.A., Tokmachev M.S., Fishman B.B. Statistika v meditsine i biologii. V 2-kh t. T.1 [Statistics in medicine and biology. In 2 volumes. Volume 1]. Moscow: Meditsina, 2000. 412 p.
2. Zaytsev V.M., Liflyandskiy V.G., Marinkin V.I. Prikladnaya meditsinskaya statistika [Applied medical statistics]. Saint Petersburg: FOLIANT, 2003. 432 p.
3. Brock G.B., McMahon C.G., Chen K.K. et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. Journal of Urology, 2002, no. 10, pp. 1332–1336.
4. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. International Journal of Clinical Practice, 2002, no. 6, pp. 453–459.
5. Eardley I., Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. International Journal of Clinical Practice, 2002, no. 4, pp. 300–304.
6. Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Natural Review of Drug Discovery, 2002, no. 9, pp. 674–682.
7. Yuan J.Q., Mao C., Wong S.Y. et al. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine, 2015, no. 7, pp. 415–422.
8. Hayashi K., Fukagai T., Koshikiya A. et al. Effect of tadalfil that was additionally administered to patients receiving an alpha1-blocker in Japanese men with lower urinary thact symptoms suggestive of benign prostatic hyperplasia. Nihon Hinyokika Gakkai Zasshi, 2016, no. 1, pp. 28–33.
9. Eardley I. Does it matter how tadalafil improves lower urinary tract symptoms? European Urology, 2015, no. 1, pp. 123–124.
10. Balhara Y.P., Sarkar S., Gupta R. Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Endocrinology and Metabolism, 2015, no. 4, pp. 451–461.
11. Hakky T.S., Jain L. Current use of phosphodiesterase inhibitors in urology. Turkish Journal of Urology, 2015, no. 1, pp. 88–92.
12. Urologiya: natsionalʹnoe rukovodstvo, pod red. N.A. Lopatkina [Urology: national leadership. Ed. by N.A. Lopatkin]. Moscow: GEHOTAR-Media, 2009. 1024 p.
13. Integrativnaya urologiya. Rukovodstvo dlya vrachey, pod red. P.V. Glybochko, Yu.G. Alyaeva [Integrative urology. Guide for doctors. Ed. by P.V. Glybochko, Yu.G. Alyaev]. Moscow: Medforum, 2014. 432 p.
14. Loran O.B., Segal A.S. System of total assessment of symptoms in chronic prostatitis. Urologiya, 2001, no. 5, pp. 16–19 (in Russ.).
15. Rosen R.C., Cappelleri J.C., Smith M.D., Lipsky J., Pena B.M. Constructing and evaluating the «Sexual Health Inventory for Men: IIEF-5» as a diagnostic tool for erectile dysfunction (ED). International Journal of Impotence Research, 1998, no. 10, no. S3–S35.
16. Khafizʹyanova R.Kh., Burykin I.M., Aleeva G.N. Matematicheskaya statistika v ehksperimentalʹnoy i klinicheskoy farmakologii [Mathematical statistics in experimental and clinical pharmacology]. Kazan: Meditsina, 2006. Pp. 102–104.